title: A case of recipient bed melt and wound dehiscence after penetrating keratoplasty and subconjunctival injection of bevacizumab.
abstract: We describe a case of recipient bed melt and wound dehiscence after uneventful penetrating keratoplasty and subconjunctival injection of bevacizumab. Three weeks postoperatively, the patient presented with limbal ischemia, recipient bed melt, and wound dehiscence corresponding to the area of bevacizumab injection. The melt was managed by application of cyanoacrylate glue along with bandage contact lens. Although the graft survived, there was a problem in re-epithelization. This case highlights the need for further studies to elucidate the therapeutic dose, side effects, and correct timing of using bevacizumab with respect to corneal transplant surgery.
authors.affiliation: Ratan Jyoti Netralaya, Ophthalmic Institute and Research Centre, Gwalior, India.
authors.forename: Purendra
authors.initials: P
authors.lastname: Bhasin
authors.forename: Prateek
authors.initials: P
authors.lastname: Gujar
authors.forename: Priyamvada
authors.initials: P
authors.lastname: Bhasin
mesh_terms: D000328:Adult; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D000068258:Bevacizumab; D003228:Conjunctiva; D003320:Corneal Ulcer / Q000188:drug therapy / Q000209:etiology*; D003487:Cyanoacrylates / Q000627:therapeutic use; D006085:Graft Survival; D006801:Humans; D056965:Injections, Intraocular; D015948:Keratoplasty, Penetrating; D008297:Male; D011183:Postoperative Complications; D013529:Surgical Wound Dehiscence / Q000188:drug therapy / Q000209:etiology*; D014014:Tissue Adhesives / Q000627:therapeutic use; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D003487:Cyanoacrylates; D014014:Tissue Adhesives; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; C040229:MK 6 cyanoacrylate